Iovance Biotherapeutics, Inc. (IOVA) Stock Grade

About Iovance Biotherapeutics, Inc.'s fundamentals

Iovance Biotherapeutics is a biotech company with a market capitalization of $975.6 million that is experiencing significant revenue expansion, growing 60.6% year-over-year. However, the company is currently unprofitable, posting a net loss in its latest annual statement with a net margin of -148.4%, meaning it is spending substantially more than it generates in revenue. The company does not pay a dividend, which is typical for development-stage biotech firms prioritizing cash deployment toward research and commercialization efforts.